2.35. Analysis.
Comparison 2 Leukotriene Receptor Antagonists (LTRA) + ICS vs. DOUBLE dose of ICS in SYMPTOMATIC PATIENTS, Outcome 35 Death at HIGHER THAN LICENSED DOSES.
Comparison 2 Leukotriene Receptor Antagonists (LTRA) + ICS vs. DOUBLE dose of ICS in SYMPTOMATIC PATIENTS, Outcome 35 Death at HIGHER THAN LICENSED DOSES.